Oleg Nodelman joins Galapagos’ Board of Directors
07-10-2024 Galapagos has announced the appointment of Oleg Nodelman as a new member of the Board of Directors, effective October 7, 2024.
Oleg Nodelman has extensive experience in the biotech sector and the scientific community. He previously served as Non-Executive Director at Addex Pharmaceuticals and Kindred Bio, and as a member of the President’s Council at The Gladstone. Additionally, he is the founder and portfolio manager of EcoR1 Capital LLC, an investment advisory firm focused on biotechnology, investing in companies at all stages of research and development.
Nodelman has been appointed as a Non-Executive, Non-Independent Director on the Galapagos Board of Directors, representing EcoR1, one of the company’s largest shareholders. He replaces Dan Baker, who stepped down on October 6, 2024.
Dr. Paul Stoffels, CEO of Galapagos and Chairman of the Board, expressed his enthusiasm about Nodelman’s appointment: 'His deep expertise in biotech and shared goals of unlocking further value for Galapagos will be instrumental in helping us execute our near- and long-term strategy and deliver superior results for patients, shareholders, employees, and customers.'